PMID- 11878202
OWN - NLM
STAT- MEDLINE
DCOM- 20020327
LR  - 20071115
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 52
IP  - 2
DP  - 2002
TI  - [Comparison beta-blockers and their relevance to pharmacologic therapy of 
      cardiovascular diseases].
PG  - 73-80
AB  - beta-Blockers have regained interest in the treatment of cardiovascular diseases 
      after a period of decreasing importance due to the introduction of other 
      cardiovascular treatment principles. beta-blockers expose the longest list of 
      indications in cardiovascular therapy available and present positive mortality 
      results for the treatment of arterial hypertension, the postinfarction situation 
      and heart failure. There are three indications for the treatment of atrial 
      fibrillation alone: slowing of AV-conductance, sinus rhythm restoration and 
      atrial stabilization. Among the most recent developments there is the clear 
      establishment of evidence for their life prolonging activity in heart failure 
      treatment which has been proven for carvedilol, bisoprolol and metoprolol in NYHA 
      (New York Heart Association) stages 2 and 3 and so far for carvedilol only in 
      NYHA stage 4. Differences between beta-blocking agents are clinically most 
      relevant for the presence of an intrinsic sympathomimetic activity (ISA) which 
      should no longer be present in clinically used compounds. The ISA of bucindolol 
      is the most likely reason for its failure in an outcome study for heart failure 
      treatment. Other pharmacological distinctions relate to the selectivity in the 
      beta-adrenergic system, activity in the alpha-adrenergic system and differences 
      in metabolism and elimination.
FAU - Wehling, Martin
AU  - Wehling M
AD  - Institut fur Klinische Pharmakologie, Klinikum Mannheim GmbH, 
      Universitatsklinikum, Fakultat fur Klinische Medizin Mannheim, 
      Ruprecht-Karls-Universitat Heidelberg, Mannheim. 
      martin.wehling@kpha.ma.uni-heidelberg.de
LA  - ger
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - beta-Blocker und ihre Bedeutung fur die Pharmakotherapie kardiovaskularer 
      Erkrankungen im Vergleich.
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Anti-Arrhythmia Agents)
SB  - IM
MH  - Adrenergic beta-Antagonists/*therapeutic use
MH  - Anti-Arrhythmia Agents/therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Heart Failure/drug therapy
MH  - Humans
MH  - Hypertension/drug therapy
MH  - Myocardial Infarction/prevention & control
RF  - 33
EDAT- 2002/03/07 10:00
MHDA- 2002/03/28 10:01
CRDT- 2002/03/07 10:00
PHST- 2002/03/07 10:00 [pubmed]
PHST- 2002/03/28 10:01 [medline]
PHST- 2002/03/07 10:00 [entrez]
AID - 10.1055/s-0031-1299860 [doi]
PST - ppublish
SO  - Arzneimittelforschung. 2002;52(2):73-80. doi: 10.1055/s-0031-1299860.